Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Yorkville University, Fredericton, NB, Canada.
BMC Psychiatry. 2023 Feb 2;23(1):85. doi: 10.1186/s12888-022-04379-z.
Structured care pathways (SCPs) consist of treatment algorithms that patients advance through with the goal of achieving remission or response. These SCPs facilitate the application of current evidence and adequate treatment, which potentially benefit patients with mood disorders. The aim of this systematic review was to provide an updated synthesis of SCPs for the treatment of depressive disorders and bipolar disorder (BD).
PubMed, PsycINFO, and Embase were searched through June 2022 for peer-reviewed studies examining outcomes of SCPs. Eligibility criteria included being published in a peer-reviewed journal in the English language, reporting of intervention used in the SCP, and having quantitative outcomes. Studies Cochrane risk of bias tool was used to assess quality of RCTs.
Thirty-six studies including 15,032 patients were identified for qualitative synthesis. Six studies included patients with BD. The studies were highly heterogeneous in design, outcome measures, and algorithms. More than half of the studies reported superiority of SCPs over treatment as usual, suggesting that the standardized structure and consistent monitoring inherent in SCPs may be contributing to their effectiveness. We also found accumulating evidence supporting feasibility of SCPs in different settings, although dropout rates were generally higher in SCPs. The studies included were limited to being published in peer-reviewed journals in English language. The heterogeneity of studies did not allow quantitative evaluation.
The findings of our study suggest that SCPs are equally or more effective than treatment as usual in depression and BD. Further studies are required to ascertain their effectiveness, particularly for BD, and to identify factors that influence their feasibility and success.
结构化护理路径(SCP)由一系列治疗算法组成,患者按照这些算法进行治疗,以达到缓解或应答的目标。这些 SCP 有助于应用当前的证据和适当的治疗,从而使情绪障碍患者受益。本系统评价的目的是提供治疗抑郁障碍和双相情感障碍(BD)的 SCP 的最新综合研究。
通过 2022 年 6 月在 PubMed、PsycINFO 和 Embase 上搜索同行评议研究,以检查 SCP 的结果。纳入标准包括以英文在同行评议期刊上发表、报告 SCP 中使用的干预措施以及具有定量结果的研究。研究使用 Cochrane 偏倚风险工具评估 RCT 的质量。
确定了 36 项包括 15032 名患者的研究进行定性综合。有 6 项研究纳入了 BD 患者。这些研究在设计、结局测量和算法方面存在高度异质性。超过一半的研究报告 SCP 优于常规治疗,这表明 SCP 固有的标准化结构和一致监测可能有助于其疗效。我们还发现越来越多的证据支持 SCP 在不同环境中的可行性,尽管 SCP 的辍学率普遍较高。纳入的研究仅限于在同行评议的英文期刊上发表。研究的异质性不允许进行定量评估。
我们的研究结果表明,SCP 在抑郁和 BD 中的疗效与常规治疗相当或更优。需要进一步的研究来确定其疗效,特别是对于 BD,并确定影响其可行性和成功的因素。